JP4709758B2 - 呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体 - Google Patents

呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体 Download PDF

Info

Publication number
JP4709758B2
JP4709758B2 JP2006523677A JP2006523677A JP4709758B2 JP 4709758 B2 JP4709758 B2 JP 4709758B2 JP 2006523677 A JP2006523677 A JP 2006523677A JP 2006523677 A JP2006523677 A JP 2006523677A JP 4709758 B2 JP4709758 B2 JP 4709758B2
Authority
JP
Japan
Prior art keywords
methyl
indole
acetic acid
phenoxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006523677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502804A (ja
JP2007502804A5 (enExample
Inventor
ロジャー・ビクター・ボナート
アンソニー・ロナルド・クック
ティモシー・ジョン・ルーカー
ルクサナ・タスニーム・モハンメド
スティーブン・トム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007502804A publication Critical patent/JP2007502804A/ja
Publication of JP2007502804A5 publication Critical patent/JP2007502804A5/ja
Application granted granted Critical
Publication of JP4709758B2 publication Critical patent/JP4709758B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006523677A 2003-08-18 2004-08-16 呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体 Expired - Fee Related JP4709758B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0302232A SE0302232D0 (sv) 2003-08-18 2003-08-18 Novel Compounds
SE0302232-4 2003-08-18
PCT/GB2004/003502 WO2005019171A1 (en) 2003-08-18 2004-08-16 Substituted indole derivatives for pharmaceutical composition for treating respiratory diseases

Publications (3)

Publication Number Publication Date
JP2007502804A JP2007502804A (ja) 2007-02-15
JP2007502804A5 JP2007502804A5 (enExample) 2007-09-27
JP4709758B2 true JP4709758B2 (ja) 2011-06-22

Family

ID=28450248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523677A Expired - Fee Related JP4709758B2 (ja) 2003-08-18 2004-08-16 呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体

Country Status (18)

Country Link
US (1) US7709521B2 (enExample)
EP (1) EP1656347B1 (enExample)
JP (1) JP4709758B2 (enExample)
AR (1) AR045462A1 (enExample)
AT (1) ATE484494T1 (enExample)
CY (1) CY1110977T1 (enExample)
DE (1) DE602004029580D1 (enExample)
DK (1) DK1656347T3 (enExample)
ES (1) ES2352201T3 (enExample)
MY (1) MY143367A (enExample)
PL (1) PL1656347T3 (enExample)
PT (1) PT1656347E (enExample)
SA (1) SA04250255B1 (enExample)
SE (1) SE0302232D0 (enExample)
SI (1) SI1656347T1 (enExample)
TW (1) TW200510303A (enExample)
UY (1) UY28473A1 (enExample)
WO (1) WO2005019171A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
DE602005006539D1 (de) 2004-03-11 2008-06-19 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivate
PL1833791T3 (pl) 2004-12-27 2011-12-30 Actelion Pharmaceuticals Ltd Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
EP1911759A4 (en) 2005-07-22 2010-07-21 Shionogi & Co AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
ES2372701T3 (es) 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
GB0521275D0 (en) * 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
WO2007138282A2 (en) 2006-05-26 2007-12-06 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
US20150072963A1 (en) * 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
WO2007149312A2 (en) 2006-06-16 2007-12-27 The Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
AU2007279079A1 (en) 2006-07-22 2008-01-31 Oxagen Limited Compounds having CRTH2 antagonist activity
PT2051962E (pt) 2006-08-07 2012-01-10 Actelion Pharmaceuticals Ltd Derivados do ácido (3-amino-1,2,3,4-tetrahidro-9hcarbazol- 9-il)-acético
HRP20130900T1 (hr) 2007-04-11 2013-11-08 Kissei Pharmaceutical Co., Ltd. Derivat (aza)indola i njegova uporaba u medicinske svrhe
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
PT2229358E (pt) 2007-12-14 2011-06-29 Pulmagen Therapeutics Asthma Ltd Indoles e sua utilização terapêutica
SI2250161T1 (sl) 2008-01-18 2014-04-30 Atopix Therapeutics Limited Spojine, ki imajo aktivnost crth2 antagonista
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509990A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
MY150774A (en) * 2008-12-25 2014-02-28 Taisho Pharmaceutical Co Ltd Isoquinoline derivative
AR076590A1 (es) * 2009-05-19 2011-06-22 Vivia Biotech Sl Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos
EP2451780B1 (en) * 2009-07-06 2013-06-19 AstraZeneca AB Intermediates and processes for the preparation of 4-(acetylamino))-3-[(4-chloro-phenyl)thio]-2-methyl-1h-indole-1-acetic acid
BR112012020273A8 (pt) * 2010-02-11 2017-12-26 Univ Vanderbilt compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica
NZ603108A (en) 2010-03-22 2014-05-30 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2586772A4 (en) 2010-06-23 2013-11-13 Taisho Pharmaceutical Co Ltd isoquinoline
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
HUE028972T2 (en) 2011-04-14 2017-01-30 Actelion Pharmaceuticals Ltd 7- (Heteroarylamino) -6,7,8,9-tetrahydropyrido [1,2-a] indole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
KR102205774B1 (ko) * 2012-03-21 2021-01-20 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 모발 성장을 조절하는 방법 및 조성물
CN106103435B (zh) 2014-03-17 2018-11-16 爱杜西亚药品有限公司 氮杂吲哚乙酸衍生物及彼等作为前列腺素d2受体调节剂的用途
MX2016011900A (es) 2014-03-18 2016-12-05 Actelion Pharmaceuticals Ltd Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
EP4420734A3 (en) 2015-02-13 2024-11-06 Institut National de la Santé et de la Recherche Médicale Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
MX2018001217A (es) 2015-07-30 2018-09-12 Univ Pennsylvania Alelos polimorficos de nucleotidos individuales del gen humano dp-2 para la deteccion de la susceptibilidad a la inhibicion del crecimiento del cabello por pgd2.
PL3350179T3 (pl) 2015-09-15 2021-08-02 Idorsia Pharmaceuticals Ltd Krystaliczne postacie
WO2022092141A1 (ja) * 2020-10-28 2022-05-05 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
EP0686148A4 (en) 1993-02-24 1996-02-07 Merck & Co Inc INHIBITORS OF HIV INVERSE TRANSCRIPTASE
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
WO1999009007A1 (en) 1997-08-21 1999-02-25 American Home Products Corporation Solid phase synthesis of 2,3-disubstituted indole compounds
ES2198033T3 (es) 1997-12-19 2004-01-16 Eli Lilly And Company Compuestos de imidazolina hipoglucemicos.
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
WO2001032621A1 (en) 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Novel indole derivatives and drugs containing the same as the active ingredient
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
IL152682A0 (en) * 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
MXPA04007414A (es) 2002-02-01 2004-10-11 Hoffmann La Roche Indoles sustituidos como agonistas alfa-1.
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
US7534897B2 (en) * 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
US20070232681A1 (en) 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
WO2007138282A2 (en) 2006-05-26 2007-12-06 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
EP2037910A1 (en) 2006-06-08 2009-03-25 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
CA2656150A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis New cxcr2 inhibitors

Also Published As

Publication number Publication date
JP2007502804A (ja) 2007-02-15
PT1656347E (pt) 2010-12-09
SI1656347T1 (sl) 2011-01-31
SA04250255B1 (ar) 2009-02-25
DK1656347T3 (da) 2011-01-10
US7709521B2 (en) 2010-05-04
EP1656347B1 (en) 2010-10-13
WO2005019171A1 (en) 2005-03-03
DE602004029580D1 (de) 2010-11-25
ATE484494T1 (de) 2010-10-15
MY143367A (en) 2011-04-29
CY1110977T1 (el) 2015-06-11
ES2352201T3 (es) 2011-02-16
AR045462A1 (es) 2005-10-26
US20060264444A1 (en) 2006-11-23
PL1656347T3 (pl) 2011-02-28
EP1656347A1 (en) 2006-05-17
TW200510303A (en) 2005-03-16
SE0302232D0 (sv) 2003-08-18
UY28473A1 (es) 2005-03-31

Similar Documents

Publication Publication Date Title
JP4709758B2 (ja) 呼吸器系疾患の処置用医薬組成物のための置換インドール誘導体
JP4541361B2 (ja) 新規３位硫黄置換インドール
JP2007512299A (ja) 呼吸器系疾患の処置に有用な１−酢酸−インドール、−インダゾールおよび−ベンズイミダゾール誘導体
JP4588018B2 (ja) 新規化合物
JP2009538289A (ja) ビアリールまたはヘテロアリール置換インドール
HK1090635B (en) Substituted 3-sulfur indoles
HK1126773B (en) Use of 3-phenylthio-1h-indole-1-acetic acid derivatives as modulators of crth2 receptor activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20101110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110318

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees